EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring

Eleonora Cecchin, Marco Orleni iD, Sara Gagno iD, Marcella Montico iD, Elena Peruzzi iD, Rossana Roncato iD, Lorenzo Gerratana, Serena Corsetti, Fabio Puglisi iD, Giuseppe Toffoli iD, Erika Cecchin iD, Bianca Posocco iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms251910453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Eleonora Cecchin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Experimental and Clinical Pharmacology Unit- CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, Italy. Hauptthemen laut MEDLINE: Piperazines, Pyridines, Tandem Mass Spectrometry, Drug Monitoring. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centro Regionale di Farmacovigilanza (AIFA funds 2015-2016- 2017).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic drug monitoring (TDM) may be beneficial for cyclin-dependent kinase 4/6 inhibitors (CDK4/6is), such as palbociclib, ribociclib, and abemaciclib, due to established exposure–toxicity relationships and the potential for monitoring treatment adherence. Developing a method for quantifying CDK4/6is, abemaciclib metabolites (M2, M20), and letrozole in dried blood spots (DBS) could be useful to enhance the feasibility of TDM. Thus, an optimized LC-MS/MS method was developed using the HemaXis DB10 device for volumetric (10 µL) DBS collection. Chromatographic separation was achieved using a reversed-phase XBridge BEH C18 column. Detection was performed with a triple quadrupole mass spectrometer, utilizing ESI source switching between negative and positive ionization modes and multiple reaction monitoring acquisition. Analytical validation followed FDA, EMA, and IATDMCT guidelines, demonstrating high selectivity, adequate sensitivity (LLOQ S/N ≥ 30), and linearity (r ≥ 0.997). Accuracy and precision met acceptance criteria (between-run: accuracy 95–106%, CV ≤ 10.6%). Haematocrit independence was confirmed (22–55%),with high recovery rates (81–93%) and minimal matrix effects (ME 0.9–1.1%). The stability of analytes under home-sampling conditions was also verified. Clinical validation supports DBS-based TDM as feasible, with conversion models developed for estimating plasma concentrations (the reference for TDM target values) of letrozole, abemaciclib, and its metabolites. Preliminary data for palbociclib and ribociclib are also presented.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperazinesPyridinesTandem Mass SpectrometryDrug MonitoringPurinesLetrozoleBenzimidazolesAminopyridinesDried Blood Spot TestingHumansChromatography, LiquidCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Protein Kinase InhibitorsLiquid Chromatography-Mass Spectrometry

Stichwörter der Autor:innen

Ctroughabemaciclibdried blood spotletrozolemass spectrometrypalbociclibplasma exposureribociclibtherapeutic drug monitoring

Substanzen

palbociclibabemaciclibribociclibPiperazinesPyridinesPurinesLetrozoleBenzimidazolesAminopyridinesCyclin-Dependent Kinase 6

Autor:innen und Institutionen

  • Experimental and Clinical Pharmacology Unit- CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, Italy.
  • Doctoral School in Pharmacological Sciences, University of Padua, 35131 Padova, Italy.
  • Clinical Trial Office, Scientific Direction- CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, Italy.
  • Department of Medical Oncology- CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, Italy.
  • Department of Medicine, University of Udine, 33100 Udine, Italy.

ORCID-Profile: Marco Orleni, Sara Gagno, Marcella Montico, Elena Peruzzi, Rossana Roncato, Fabio Puglisi, Giuseppe Toffoli, Erika Cecchin, Bianca Posocco

Förderung

  • Centro Regionale di Farmacovigilanza (AIFA funds 2015-2016- 2017)

Zitieren

APA

Cecchin, E., Orleni, M., Gagno, S., Montico, M., Peruzzi, E., Roncato, R., Gerratana, L., Corsetti, S., Puglisi, F., Toffoli, G., Cecchin, E., & Posocco, B. (2024). Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910453

Vancouver

Cecchin E, Orleni M, Gagno S, Montico M, Peruzzi E, Roncato R, et al. Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910453

BibTeX
@article{Cecchin2024,
  author = {Cecchin, Eleonora and Orleni, Marco and Gagno, Sara and Montico, Marcella and Peruzzi, Elena and Roncato, Rossana and Gerratana, Lorenzo and Corsetti, Serena and Puglisi, Fabio and Toffoli, Giuseppe and Cecchin, Erika and Posocco, Bianca},
  title = {Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms251910453}
}
Kostenlos starten →